Finding them in violation of competition norms, the fair trade watchdog has passed orders against All India Organization of Chemists and Druggists (AIOCD) and its affiliates -- All Kerala Chemists & Druggists Association (AKCDA), Assam Drug Dealers Association (ADDA) and Barpeta Drugs Dealers Association (BDDA).
Further, the Competition Commission of India (CCI) has slapped penalty of Rs 5.61 lakh on ADDA. Since their financial statements were not immediately available, the regulator said that fine on drug associations of Kerala and Barpeta would decided later at an appropriate time.
As a fine of Rs 47.40 lakh was already slapped on AIOCD in an earlier case for similar violations, the Commission said it "does not consider it appropriate to impose any further monetary penalty" on this association.
In two separate orders, the Commission has all these associations to "cease and desist from indulging in and following the practices which have been found anti-competitive in violation...Of the (Competition) Act".
The rulings, dated December 9, came on complaints that these associations were abusing their dominant position by limiting and restricting supply of pharmaceutical drugs.
A probe by the Director General (DG) -- the investigation arm of the Commission -- found that AIOCD and its affiliated associations resorted to the practice of boycott of pharmaceutical companies and their products to enforce certain requirements related to 'No Objection Certificate (NOC)', 'Product Information Service (PIS)' and fixed trade margins, among others.
As per the findings, the pharmaceutical firms often stop supplies to the stockists under the threat of boycott of sale or purchase of the products of the company by the AIOCD and its affiliated associations, CCI said in one of the orders.
CCI has also asked AIOCD and its other affiliates to file an undertaking that the practices carried on by their members on the issue of grant of NOC for appointment of stockists, fixation of trade margins, collection of PIS charges and boycott of products of pharma firma have been discontinued.
Among others, it has also asked to inform all chemists and druggists and all its members and associations that they were free to give discounts to the customers.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
